GFPC
JAZZ icon

Global Financial Private Client’s Jazz Pharmaceuticals JAZZ Stock Holding History

Global Financial Private Client’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12
Closed -$1.49K – 908
2025
Q1 		$1.49K Buy
12
+8
+200% +$1.04K ﹤0.01% 952
2024
Q4 		$493 Sell
4
-44
-92% -$5.19K ﹤0.01% 945
2024
Q3 		$5.35K Buy
+48
New +$5.26K ﹤0.01% 634

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Global Financial Private Client's JAZZ Position: Q2 2025 in Review

Global Financial Private Client sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 12 shares — an estimated $1.49K sold.

Global Financial Private Client first reported a position in JAZZ in Q3 2024 and held it in 3 quarters. The position peaked at $5.35K in Q3 2024. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Global Financial Private Client reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Global Financial Private Client sold 12 Jazz Pharmaceuticals shares in Q2 2025, an estimated $1.49K.
  • Global Financial Private Client first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Global Financial Private Client's Jazz Pharmaceuticals position peaked at $5.35K in Q3 2024.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.